The DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.
Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases
Open accessAbstract
Fibrosis is the end result of persistent inflammatory responses induced by a variety of stimuli, including chronic infections, autoimmune reactions, and tissue injury. Fibrotic diseases affect all vital organs and are characterized by a high rate of morbidity and mortality in the developed world. Until recently, there were no approved antifibrotic therapies. In recent years, high levels of interleukin-17 (IL-17) have been associated with chronic inflammatory diseases with fibrotic complications that culminate in organ failure. In this review, we provide an update on the role of IL-17 in fibrotic diseases, with particular attention to the most recent lines of research in the therapeutic field represented by the epigenetic mechanisms that control IL-17 levels in fibrosis. A better knowledge of the IL-17 signaling pathway implications in fibrosis could design new strategies for therapeutic benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stiff matrices activate ILK-STAT3 and YAP/TAZ signaling, enhancing RORgt expression and promoting Th17 differentiation.”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [86]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“DNA demethylation, generally linked with gene silencing, has recently been identified as a strategy in the regulation of IL-17-dependent fibrosis.”
Unique features of long non-coding RNA biogenesis and function
Quinn, J. J., & Chang, H. Y. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.10 · Cited by 3,672 · cited 1×
“This would be essential to identify not only new therapies but also predictive biomarkers for the diagnosis of fibrotic diseases, such as many autoimmune diseases.”
Interleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372 · cited 1×
“IL-17A and F are the closest members, with 50% homology, followed by IL-17B (29%), IL-17D (25%), and IL-17C (23%); IL-17E displays the lowest degree of sequence conservation (16%), implicating that IL-17E is the most dissimilar protein [19,20].”
Long non-coding RNAs: definitions, functions, challenges and recommendations
Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L.-L., Chen, R., Dean, C., Dinger, M. E., Fitzgerald, K. A., et al. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00566-8 · Cited by 2,356 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989 · cited 2×
“Many studies have revealed that miRNAs and lncRNAs are key regulators of the development of fibrotic processes, often correlated with autoimmune conditions.”
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971 · cited 1×
“These data confirmed that cytokines drive the acute and chronic inflammatory responses that culminate in fibrosis activation [8].”
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 1×
“Interestingly, in pathological disorders that are based on inflammatory processes, altered repair mechanisms can lead to the formation of fibrotic tissue upon wound healing [4], which may be responsible for aberrant tissue repair [1].”
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 1×
“In liver fibrosis, IL-17, operating in synergy with IL-1 β , IL-6, and IL-23, continues the inflammatory process by promoting transforming growth factor-β (TGF β ) expression in hepatic stellate cells [48,49].”
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 1×
“IL-17A and IL-17F link to a dimeric IL17RA/RC system; IL-17B and IL-17E link to a dimeric 17RA/RB system; and IL-17C links to the IL17RA/RE complex [26].”
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443 · cited 4×
“IL-17RA and IL-17RC, acting through the binding of the SEFIR domain with the ubiquitin ligase Act1, activate the TRAF6/TAK1/NF-κ B pathway and the TRAF6/TAK1/MAPK/AP1 pathway [28].”
InfluentialWei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152 · cited 1×
“Recently, in addition to the large number of factors involved in fibrotic evolution, a number of non-coding RNAs (ncRNAs) have been found to affect fibrotic processes.”
Human IL-17: a novel cytokine derived from T cells
Yao, Z., Painter, S. L., Fanslow, W. C., Ulrich, D., Macduff, B. M., Spriggs, M. K., & Armitage, R. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.12.5483 · Cited by 1,021 · cited 1×
“IL-17A was first identified in 1993 [14] and named human cytotoxic T lymphocyte-associated antigen 8 (CTLA8).”
IL-17 and IL-17-producing cells in protection versus pathology
Mills, K. H. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00746-9 · Cited by 1,000 · cited 1×
“However, if dysregulated, IL-17A responses can promote the development and chronicity of inflammatory disorders in a number of autoimmune diseases [34,35].”
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A.-M., Painter, S. L., Comeau, M. R., Cohen, J. I., & Spriggs, M. K. (1995) · Immunity · doi:10.1016/1074-7613(95)90070-5 · Cited by 994 · cited 1×
“Among the IL-17R family members, IL-17RA is the best-known receptor [23–25].”
Interleukin-17 family and IL-17 receptors
Moseley, T. A., Haudenschild, D. R., Rose, L., & Reddi, A. H. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00002-9 · Cited by 918
TETonic shift: biological roles of TET proteins in DNA demethylation and transcription
Pastor, W. A., Aravind, L., & Rao, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3589 · Cited by 897 · cited 1×
“Actually, numerous clinical trials of anti-IL-17A and IL-17RA antibodies are currently in progress [130,131].”
Du, C., Liu, C., Kang, J., Zhao, G., Ye, Z., Huang, S., Li, Z., Wu, Z., & Pei, G. (2009) · Nature Immunology · doi:10.1038/ni.1798 · Cited by 811 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785 · cited 1×
“Both in humans and in mice, IL-17 cytokines are produced by a broad spectrum of cell types that operate on multiple cellular targets [28,30,31], triggering the secretion of pro-inflammatory cytokines, chemokines, and prostaglandins [28,32].”
Rouvier, E., Luciani, M. F., Mattéi, M. G., Denizot, F., & Golstein, P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.12.5445 · Cited by 775 · cited 1×
“The IL-17 family is a recently identified system of secretory regulatory peptides that show homology in amino acid sequences, including an extremely preserved cysteine-knot fold structure [12,13].”
Regulation of inflammatory responses by IL-17F
Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071978 · Cited by 739 · cited 1×
“IL-17, through its binding to the IL-17 receptors (IL-17Rs), is involved in chronic and persistent inflammation, autoimmunity, and the maintenance of epithelial layer integrity [21].”
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637 · cited 2×
“Interestingly, in pathological disorders that are based on inflammatory processes, altered repair mechanisms can lead to the formation of fibrotic tissue upon wound healing [4], which may be responsible for aberrant tissue repair [1].”
Hymowitz, S. G., Filvaroff, E. H., Yin, J., Lee, J., Cai, L., Risser, P., Maruoka, M., Mao, W., Foster, J., Kelley, R. F., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.19.5332 · Cited by 548 · cited 2×
“The IL-17A gene is inserted on the 6p12 chromosome, and human IL-17A is a homodimeric protein of 35 kDa that shares a different glycosylation [15,16].”
The Role of IL-17 and related cytokines in inflammatory autoimmune diseases
Kuwabara, T., Ishikawa, F., Kondo, M., & Kakiuchi, T. (2017) · Mediators of Inflammation · doi:10.1155/2017/3908061 · Cited by 519 · cited 1×
“Recently, IL-17, a pro-inflammatory cytokine, has received growing attention derived from published results collected from the study of the correlation between inflammation and autoimmune diseases [9–11].”
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Patel, D. D., & Kuchroo, V. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.12.003 · Cited by 486 · cited 1×
“Both in humans and in mice, IL-17 cytokines are produced by a broad spectrum of cell types that operate on multiple cellular targets [28,30,31], triggering the secretion of pro-inflammatory cytokines, chemokines, and prostaglandins [28,32].”
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner
Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J., et al. (2011) · Nature Immunology · doi:10.1038/ni.2156 · Cited by 477
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418 · cited 2×
“Confirming the pro-fibrotic role of IL-17A, blocking IL-17A through the intraperitoneal administration of an antibody against IL-17A reduces the acute inflammatory and fibrotic features in an experimental animal model [58].”
IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1
Lee, J., Ho, W.-H., Maruoka, M., Corpuz, R. T., Baldwin, D. T., Foster, J. S., Goddard, A. D., Yansura, D. G., Vandlen, R. L., Wood, W. I., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008289200 · Cited by 405
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402 · cited 2×
“Among the IL-17R family members, IL-17RA is the best-known receptor [23–25].”
IL-25 regulates Th17 function in autoimmune inflammation
Kleinschek, M. A., Owyang, A. M., Joyce-Shaikh, B., Langrish, C. L., Chen, Y., Gorman, D. M., Blumenschein, W. M., McClanahan, T., Brombacher, F., Hurst, S. D., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061738 · Cited by 396 · cited 1×
“Therefore, IL-17E induces expression of IL-4, IL-5, and IL-13, all of which are associated with type 2 immunity [46], and is able to promote epithelial-cell hyperplasia by increasing mucus secretion and hyperreactivity of the airway epithelium [47].”
Owyang, A. M., Zaph, C., Wilson, E. H., Guild, K. J., McClanahan, T., Miller, H. R. P., Cua, D. J., Goldschmidt, M., Hunter, C. A., Kastelein, R. A., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051496 · Cited by 379 · cited 1×
“Therefore, IL-17E induces expression of IL-4, IL-5, and IL-13, all of which are associated with type 2 immunity [46], and is able to promote epithelial-cell hyperplasia by increasing mucus secretion and hyperreactivity of the airway epithelium [47].”
IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis
Hams, E., Armstrong, M. E., Barlow, J. L., Saunders, S. P., Schwartz, C., Cooke, G., Fahy, R. J., Crotty, T. B., Hirani, N., Flynn, R. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315854111 · Cited by 376 · cited 2×
“However, the field of investigation into the pro-fibrotic activity of IL-17F is still pioneering.”
Antar, S. A., Ashour, N. A., Marawan, M. E., & Al-Karmalawy, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044004 · Cited by 366 · cited 1×
“IL-17 is critical for host defense, but its role in the regulation of many chronic inflammatory, fibrotic, and/or autoimmune diseases becomes more and more evident.”
Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family
Li, H., Chen, J., Huang, A., Stinson, J., Heldens, S., Foster, J., Dowd, P., Gurney, A. L., & Wood, W. I. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.773 · Cited by 354
Monin, L., & Gaffen, S. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028522 · Cited by 339 · cited 1×
“Moreover, a conserved intracellular subdomain homologous to Toll-IL-1R (TIR) domains was revealed which could be essential for signaling downstream of the IL-1 receptor and Toll-like receptors (TLRs) [24,29].”
Ruiz de Morales, J. M. G., Puig, L., Daudén, E., Cañete, J. D., Pablos, J. L., Martín, A. O., Juanatey, C. G., Adán, A., Montalbán, X., Borruel, N., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102429 · Cited by 338 · cited 1×
“Recently, IL-17, a pro-inflammatory cytokine, has received growing attention derived from published results collected from the study of the correlation between inflammation and autoimmune diseases [9–11].”
Kawaguchi, M., Adachi, M., Oda, N., Kokubu, F., & Huang, S.-K. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.10.019 · Cited by 336 · cited 1×
“The IL-17 family is a recently identified system of secretory regulatory peptides that show homology in amino acid sequences, including an extremely preserved cysteine-knot fold structure [12,13].”
Starnes, T., Broxmeyer, H. E., Robertson, M. J., & Hromas, R. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.642 · Cited by 331
Tan, Z., Qian, X., Jiang, R., Liu, Q., Wang, Y., Chen, C., Wang, X., Ryffel, B., & Sun, B. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203013 · Cited by 330 · cited 1×
“Accordingly, inactivation of IL-17 signaling in hepatocytes diminished the fibrotic process in the liver of murine models affected by hepatitis-induced liver injury [51].”
Ichiyama, K., Chen, T., Wang, X., Yan, X., Kim, B.-S., Tanaka, S., Ndiaye-Lobry, D., Deng, Y., Zou, Y., Zheng, P., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.005 · Cited by 327 · cited 1×
“In 2016, anti-IL-17A monoclonal antibodies (mAbs), such as the IL-17 inhibitor secukinumab and the IL-17R inhibitor brodalumab, were both approved for the treatment of psoriasis [128].”
Wick, G., Grundtman, C., Mayerl, C., Wimpissinger, T.-F., Feichtinger, J., Zelger, B., Sgonc, R., & Wolfram, D. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095937 · Cited by 327 · cited 1×
“It is estimated that in the industrialized world, 45% of all deaths can be attributed to diseases where fibrosis plays a major etiological role [2,3].”
Allen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., Guillen-Guio, B., Ma, S.-F., Okamoto, T., John, A. E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30387-9 · Cited by 297 · cited 1×
“The bromodomain and extraterminal domain (BET) family proteins, consisting of BRD2, BRD3, BRD4, and BRDT, are characterized by two bromodomains that recognize and bind to lysine-acetylated histones and other acetylated proteins with different degrees of affinity.”
Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor E
Chang, S. H., Reynolds, J. M., Pappu, B. P., Chen, G., Martinez, G. J., & Dong, C. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.010 · Cited by 271 · cited 1×
“However, knowledge of the role of IL-17Ds in the exacerbation of pulmonary fibrosis remains poorly investigated and needs clarifying studies.”
Yang, D., Chen, X., Wang, J., Lou, Q., Lou, Y., Li, L., Wang, H., Chen, J., Wu, M., Song, X., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.001 · Cited by 250 · cited 1×
“IL-17Cs role in Haemophilus influenzae and cigarette smoke-induced lung inflammation has been recently reported [73], mediating the expression of neutrophilic cytokines, the recruitment of neutrophils, and lung fibrotic damage [73].”
MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients
Niimoto, T., Nakasa, T., Ishikawa, M., Okuhara, A., Izumi, B., Deie, M., Suzuki, O., Adachi, N., & Ochi, M. (2010) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-11-209 · Cited by 232 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
A Novel Cytokine Receptor-Ligand Pair
Shi, Y., Ullrich, S. J., Zhang, J., Connolly, K., Grzegorzewski, K. J., Barber, M. C., Wang, W., Wathen, K., Hodge, V., Fisher, C. L., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910228199 · Cited by 232 · cited 1×
“Once again, IL-17C production is dependent on NF-κ B/Act1 activation, determined by IL-17C binding to the receptor complex IL-17RA/IL-17RE and, in turn, MAPK signaling molecules expression [70,71].”
Memory CD4+ T Cells in Immunity and Autoimmune Diseases
Raphael, I., Joern, R. R., & Forsthuber, T. G. (2020) · Cells · doi:10.3390/cells9030531 · Cited by 230 · cited 1×
“It is now accepted that bromodomain antagonists [96] and histone H3K27me3 demethylase inhibitors [97] are able to decrease the inflammatory status linked to CD4 + T cell activation.”
BET bromodomain inhibition suppresses TH17-mediated pathology
Mele, D. A., Salmeron, A., Ghosh, S., Huang, H.-R., Bryant, B. M., & Lora, J. M. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130376 · Cited by 229 · cited 1×
“However, all monoclonal antibodies targeting the IL-17-IL-17R pathway and approved as treatments have several disadvantages, such as non-oral administration, poor tissue penetration, and various adverse effects as an escalation of the immune system’s inflammatory response.”
T cells in systemic sclerosis: a reappraisal
O'Reilly, S., Hugle, T., & van Laar, J. M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes090 · Cited by 218
Dong, L., Wang, X., Tan, J., Li, H., Qian, W., Chen, J., Chen, Q., Wang, J., Xu, W., Tao, C., et al. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12353 · Cited by 213 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Scraping fibrosis: Expressway to the core of fibrosis
Mehal, W. Z., Iredale, J., & Friedman, S. L. (2011) · Nature Medicine · doi:10.1038/nm0511-552 · Cited by 211 · cited 2×
“In the last few years, fibrotic disorders have significantly increased and negatively impacted public health [2].”
Nakashima, T., Jinnin, M., Yamane, K., Honda, N., Kajihara, I., Makino, T., Masuguchi, S., Fukushima, S., Okamoto, Y., Hasegawa, M., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100591 · Cited by 210 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
IL-1 and IL-23 Mediate Early IL-17A Production in Pulmonary Inflammation Leading to Late Fibrosis
Gasse, P., Riteau, N., Vacher, R., Michel, M.-L., Fautrel, A., di Padova, F., Fick, L., Charron, S., Lagente, V., Eberl, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023185 · Cited by 208 · cited 2×
“…demonstrated the role of IL-17A in regulating the complex interplay between lung inflammation and After BLM treatment to induce injury, IL-17A expression is upregulated, determining the release of pro-inflammatory cytokines and chemokines by endothelial cells and epithelial cells [54,57]. fibrosis.”
IL-17 in the lung: the good, the bad, and the ugly
Gurczynski, S. J., & Moore, B. B. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00344.2017 · Cited by 202 · cited 3×
“Consequently, it is not surprising that the depletion of alveolar macrophages decreased the effects of IL-17 on the activation of lung fibrosis, supporting the hypothesis that these cells are involved first in the activation, producing pro-fibrotic factors such as IL-1 β and IL-23 [59].”
InfluentialTherapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
Fragoulis, G. E., Siebert, S., & McInnes, I. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-051914-021944 · Cited by 201 · cited 1×
“Actually, numerous clinical trials of anti-IL-17A and IL-17RA antibodies are currently in progress [130,131].”
Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes
Hot, A., & Miossec, P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143768 · Cited by 201 · cited 2×
“…evolution of autoimmune diseases presents an excessive release of pro-fibrotic factors as a result of the activation of molecular cascades depending on chronic inflammation, and the recent challenge consists of identifying anti-fibrotic therapies that can also have value in autoimmune diseases.”
Bandukwala, H. S., Gagnon, J., Togher, S., Greenbaum, J. A., Lamperti, E. D., Parr, N. J., Molesworth, A. M. H., Smithers, N., Lee, K., Witherington, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212264109 · Cited by 181 · cited 1×
“Ixekizumab is a humanized IgG4 mAb that selectively binds IL-17A and prevents interactions with IL-17R [128].”
IL-17F: Regulation, signaling and function in inflammation
Chang, S. H., & Dong, C. (2009) · Cytokine · doi:10.1016/j.cyto.2008.12.024 · Cited by 169 · cited 2×
“Following aberrant activation stimuli, T helpers appear to be involved in triggering autoimmune responses against many organs, such as joints, brain, skin, gut, pancreas, salivary and lachrymal glands, and the eye.”
Castro-Villegas, C., Pérez-Sánchez, C., Escudero, A., Filipescu, I., Verdu, M., Ruiz-Limón, P., Aguirre, M. A., Jiménez-Gomez, Y., Font, P., Rodriguez-Ariza, A., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0555-z · Cited by 166
Role of miRNA and lncRNAs in organ fibrosis and aging
Ghafouri-Fard, S., Abak, A., Talebi, S. F., Shoorei, H., Branicki, W., Taheri, M., & Akbari Dilmaghani, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112132 · Cited by 162
Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation
Li, Q., Zou, J., Wang, M., Ding, X., Chepelev, I., Zhou, X., Zhao, W., Wei, G., Cui, J., Zhao, K., et al. (2014) · Nature Communications · doi:10.1038/ncomms6780 · Cited by 158 · cited 1×
“In 2016, anti-IL-17A monoclonal antibodies (mAbs), such as the IL-17 inhibitor secukinumab and the IL-17R inhibitor brodalumab, were both approved for the treatment of psoriasis [128].”
IL-17-induced NF-κB Activation via CIKS/Act1
Sønder, S. U., Saret, S., Tang, W., Sturdevant, D. E., Porcella, S. F., & Siebenlist, U. K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199547 · Cited by 149
Organ Fibrosis and Autoimmunity: The Role of Inflammation in TGFβ-Dependent EMT
Sisto, M., Ribatti, D., & Lisi, S. (2021) · Biomolecules · doi:10.3390/biom11020310 · Cited by 142
Self-citationZhu, E., Wang, X., Zheng, B., Wang, Q., Hao, J., Chen, S., Zhao, Q., Zhao, L., Wu, Z., & Yin, Z. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303488 · Cited by 140
Interleukin-17B Antagonizes Interleukin-25-Mediated Mucosal Inflammation
Reynolds, J. M., Lee, Y.-H., Shi, Y., Wang, X., Angkasekwinai, P., Nallaparaju, K. C., Flaherty, S., Chang, S. H., Watarai, H., & Dong, C. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.008 · Cited by 135 · cited 1×
“The activity of IL-17C occurs through binding to the IL-17 receptor complex, consisting of IL-17RA and IL-17RE sub-units [70].”
Epigenetics in Cardiac Fibrosis
Felisbino, M. B., & McKinsey, T. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.05.003 · Cited by 132 · cited 2×
“Positive correlations in miRNA expression and IL-17 levels have been observed in different studies related to fibrotic diseases or autoimmune diseases with a fibrotic evolution of the tissue or organs involved (Table 2).”
IL-17 Cytokines and Chronic Lung Diseases
Ritzmann, F., Lunding, L. P., Bals, R., Wegmann, M., & Beißwenger, C. (2022) · Cells · doi:10.3390/cells11142132 · Cited by 132 · cited 2×
“…evolution of autoimmune diseases presents an excessive release of pro-fibrotic factors as a result of the activation of molecular cascades depending on chronic inflammation, and the recent challenge consists of identifying anti-fibrotic therapies that can also have value in autoimmune diseases.”
Interleukin-17D regulates group 3 innate lymphoid cell function through its receptor CD93
Huang, J., Lee, H.-Y., Zhao, X., Han, J., Su, Y., Sun, Q., Shao, J., Ge, J., Zhao, Y., Bai, X., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.018 · Cited by 127 · cited 1×
“In addition, IL-17D was recently reported to bind CD93 [27].”
Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance
Saddawi-Konefka, R., Seelige, R., Gross, E. T. E., Levy, E., Searles, S. C., Washington, A., Santosa, E. K., Liu, B., O’Sullivan, T. E., Harismendy, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.075 · Cited by 126
IL ‐25 in allergic inflammation
Xu, M., & Dong, C. (2017) · Immunological Reviews · doi:10.1111/imr.12558 · Cited by 120 · cited 2×
“IL-17F shows a high homology of sequences and activities that mostly overlap with those of IL-17A [78].”
Vandeghinste, N., Klattig, J., Jagerschmidt, C., Lavazais, S., Marsais, F., Haas, J. D., Auberval, M., Lauffer, F., Moran, T., Ongenaert, M., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.036 · Cited by 117 · cited 2×
“IL-17D has a more limited expression and is detected in B lymphocytes and resting CD4 + T cells; IL-17D acts, in particular, on endothelial cells, regulating their secretion of pro-inflammatory factors [74].”
Liu, Y., Zhu, H., Su, Z., Sun, C., Yin, J., Yuan, H., Sandoghchian, S., Jiao, Z., Wang, S., & Xu, H. (2012) · International Immunology · doi:10.1093/intimm/dxs056 · Cited by 110
Cribbs, A. P., Terlecki-Zaniewicz, S., Philpott, M., Baardman, J., Ahern, D., Lindow, M., Obad, S., Oerum, H., Sampey, B. P., Mander, P. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919893117 · Cited by 109 · cited 1×
“Ixekizumab is a humanized IgG4 mAb that selectively binds IL-17A and prevents interactions with IL-17R [128].”
Interleukin-17 family members in health and disease
Chung, S.-H., Ye, X.-Q., & Iwakura, Y. (2021) · International Immunology · doi:10.1093/intimm/dxab075 · Cited by 106 · cited 1×
“Likewise, IL-17A and IL-17C, produced by epithelial cells and immune cells, promote anti-microbial protective activity in the skin and in the intestine [28,40,41].”
IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology
Nies, J. F., & Panzer, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00341 · Cited by 104 · cited 1×
“Both in humans and in mice, IL-17 cytokines are produced by a broad spectrum of cell types that operate on multiple cellular targets [28,30,31], triggering the secretion of pro-inflammatory cytokines, chemokines, and prostaglandins [28,32].”
Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis
Nie, Y., Wu, S., Xuan, Y.-H., & Yan, G. (2022) · Military Medical Research · doi:10.1186/s40779-022-00382-3 · Cited by 103
IL-17A promotes ventricular remodeling after myocardial infarction
Zhou, S.-F., Yuan, J., Liao, M.-Y., Xia, N., Tang, T., Li, J.-J., Jiao, J., Dong, W.-Y., Nie, S.-F., Zhu, Z.-F., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1176-8 · Cited by 98 · cited 1×
“Blockade of the IL-17 signaling pathway reduces cardiac fibrosis and improves myocardial contractile function [56].”
Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions
Xia, P., Fang, X., Zhang, Z., Huang, Q., Yan, K., Kang, K., Han, L., & Zheng, Z. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.09.004 · Cited by 91 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer
Bastid, J., Déjou, C., Docquier, A., & Bonnefoy, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00718 · Cited by 88 · cited 1×
“IL-17B expression was also detected in synovial tissues from patients with RA, where it is mainly produced by neutrophils and chondrocytes [39].”
IL-17B: A new area of study in the IL-17 family
Bie, Q., Jin, C., Zhang, B., & Dong, H. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.07.004 · Cited by 87 · cited 2×
“IL-17B was demonstrated to be highly expressed during the intestinal inflammatory state and is able to induce neutrophil migration upon intraperitoneal administration, suggesting a pro-inflammatory key role [18,36,37].”
Zhang, Y., Zhang, Y., Li, T., Wang, J., Jiang, Y., Zhao, Y., Jin, X., Xue, G., Yang, Y., Zhang, X., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.01.001 · Cited by 86 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Hanieh, H., & Alzahrani, A. M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343486 · Cited by 85 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Liu, X., He, F., Pang, R., Zhao, D., Qiu, W., Shan, K., Zhang, J., Lu, Y., Li, Y., & Wang, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577429 · Cited by 85 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
IL-17, IL-27, and IL-33: A Novel Axis Linked to Immunological Dysfunction During Sepsis
Morrow, K. N., Coopersmith, C. M., & Ford, M. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01982 · Cited by 85 · cited 1×
“The function of the IL-17C isoform in the progression of fibrosis was mainly explored in IPF [72], using a lipopolysaccharide-induced lung injury as a model of IPF.”
Interleukin-17A Interweaves the Skeletal and Immune Systems
Tang, M., Lu, L., & Yu, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.625034 · Cited by 85 · cited 2×
“In this context, IL-17A has been implicated in the pathogenesis of many disorders characterized by inflammatory complications, including cardiovascular and neurological diseases [33].”
Goepfert, A., Lehmann, S., Blank, J., Kolbinger, F., & Rondeau, J. (2020) · Immunity · doi:10.1016/j.immuni.2020.02.004 · Cited by 82 · cited 1×
“These receptors share a unique protein-protein interaction domain in their cytoplasmic tail called the SEF/IL-17R (SEFIR) domain [22].”
Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
Rafael‐Vidal, C., Pérez, N., Altabás‐González, I., García, S., & Pego‐Reigosa, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197100 · Cited by 81
Luo, Q., Liu, Y., Shi, K., Shen, X., Yang, Y., Liang, X., Lu, L., Qiao, W., Chen, A., Hong, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.012 · Cited by 81
Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo
Regna, N. L., Chafin, C. B., Hammond, S. E., Puthiyaveetil, A. G., Caudell, D. L., & Reilly, C. M. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.01.002 · Cited by 78 · cited 1×
“Positive correlations in miRNA expression and IL-17 levels have been observed in different studies related to fibrotic diseases or autoimmune diseases with a fibrotic evolution of the tissue or organs involved (Table 2).”
Amara, S., López, K., Banan, B., Brown, S.-K., Whalen, M. M., Myles, E. L., Ivy, M. T., Johnson, T. L., Schey, K. L., & Tiriveedhi, V. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.10.021 · Cited by 77
Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Bárcena‐Varela, M., Colyn, L., & Fernández‐Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 77 · cited 2×
“Positive correlations in miRNA expression and IL-17 levels have been observed in different studies related to fibrotic diseases or autoimmune diseases with a fibrotic evolution of the tissue or organs involved (Table 2).”
IL-17C/IL-17 Receptor E Signaling in CD4+ T Cells Promotes TH17 Cell-Driven Glomerular Inflammation
Krohn, S., Nies, J. F., Kapffer, S., Schmidt, T., Riedel, J.-H., Kaffke, A., Peters, A., Borchers, A., Steinmetz, O. M., Krebs, C. F., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017090949 · Cited by 72 · cited 2×
“IL-17D has a more limited expression and is detected in B lymphocytes and resting CD4 + T cells; IL-17D acts, in particular, on endothelial cells, regulating their secretion of pro-inflammatory factors [74].”
Interleukin-17: Friend or foe in organ fibrosis
Ramani, K., & Biswas, P. S. (2019) · Cytokine · doi:10.1016/j.cyto.2018.11.003 · Cited by 68
Dicer structure and function: conserved and evolving features
Zapletal, D., Kubíček, K., Svoboda, P., & Štefl, R. (2023) · EMBO Reports · doi:10.15252/embr.202357215 · Cited by 66 · cited 1×
“A thriving field of research concerns the inflammatory mechanisms mediated by the activation of EMT, which may have links to fibrotic evolution.”
Conti, H. R., Whibley, N., Coleman, B. M., Garg, A. V., Jaycox, J. R., & Gaffen, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122807 · Cited by 64 · cited 1×
“However, knowledge of the role of IL-17Ds in the exacerbation of pulmonary fibrosis remains poorly investigated and needs clarifying studies.”
Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation
Peng, T., Chanthaphavong, R. S., Sun, S., Trigilio, J. A., Phasouk, K., Jin, L., Layton, E. D., Li, A. Z., Correnti, C. E., De van der Schueren, W., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160581 · Cited by 60 · cited 1×
“In addition, IL-17C is also secreted by keratinocytes and cutaneous neurons, but in a specific condition, represented by the reactivation of the herpes simplex virus [42].”
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases
Klein, K. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000744 · Cited by 58 · cited 1×
“These new small-molecule drugs (SMDs), which are orally bioavail-able, are beneficial in terms of production cost, convenience of delivery, and potentially higher efficacy.”
Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis
Göschl, L., Preglej, T., Boucheron, N., Saferding, V., Müller, L., Platzer, A., Hirahara, K., Shih, H., Bäcklund, J., Matthias, P., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102379 · Cited by 58 · cited 1×
“Positive correlations in miRNA expression and IL-17 levels have been observed in different studies related to fibrotic diseases or autoimmune diseases with a fibrotic evolution of the tissue or organs involved (Table 2).”
Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
Rosine, N., & Miceli‐Richard, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553742 · Cited by 57 · cited 1×
“However, if dysregulated, IL-17A responses can promote the development and chronicity of inflammatory disorders in a number of autoimmune diseases [34,35].”
Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues
Miao, H., Wu, X., Zhang, D., Wang, Y., Guo, Y. P., Li, P., Xiong, Q., & Zhao, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105316 · Cited by 56 · cited 1×
“During the fibrotic process, an excessive accumulation of extracellular matrix (ECM) components occurs; collagen, fibronectin, and hyaluronic acid are released and synthesized to a greater level at the site of tissue injury, leading to organ failure and death [5].”
Epigenetics as a versatile regulator of fibrosis
Liu, Y., Wen, D., Ho, C., Li, Y., Zheng, D., O’Reilly, S., Gao, Y., Li, Q., & Zhang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04018-5 · Cited by 55 · cited 1×
“Indeed, BET inhibition has been shown to reduce the differentiation of naive T cells into Th17 cells [98].”
Comparative and Evolutionary Analysis of the Interleukin 17 Gene Family in Invertebrates
Huang, X., Zhang, H., & He, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132802 · Cited by 53 · cited 1×
“IL-17A and F are the closest members, with 50% homology, followed by IL-17B (29%), IL-17D (25%), and IL-17C (23%); IL-17E displays the lowest degree of sequence conservation (16%), implicating that IL-17E is the most dissimilar protein [19,20].”
Interleukin-17 and -22 synergy linking inflammation and EMT-dependent fibrosis in Sjögren’s syndrome
Sisto, M., Lorusso, L., Tamma, R., Ingravallo, G., Ribatti, D., & Lisi, S. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13337 · Cited by 53 · cited 1×
“…of IL-17 in EMT-dependent fibrosis, Sisto et al. recently demonstrated that IL-17, through the support of IL-22, contributes to triggering the EMT-dependent fibrotic process in healthy human salivary gland epithelial cells, clarifying the role of IL-17 in the fibrotic evolution observed in SS [53].”
Self-citationIncreased serum levels of miR-1266 in patients with psoriasis vulgaris
Ichihara, A., Jinnin, M., Oyama, R., Yamane, K., Fujisawa, A., Sakai, K., Masuguchi, S., Fukushima, S., Maruo, K., & Ihn, H. (2012) · European Journal of Dermatology · doi:10.1684/ejd.2011.1600 · Cited by 52 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Wang, J., Wang, C., Liu, L., Hong, S., Ru, Y., Sun, X., Chen, J., Zhang, M., Lin, N., Li, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.993057 · Cited by 52
IL-17D: A Less Studied Cytokine of IL-17 Family
Liu, X., Sun, S., & Liu, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508255 · Cited by 51 · cited 2×
“IL-17E, recently correlated with pulmonary fibrosis, was secreted by Th2 cells, epithelial cells, endothelial cells, T cells, alveolar macrophages, DCs, eosinophils, and baso-phils [75].”
IL-25 contributes to lung fibrosis by directly acting on alveolar epithelial cells and fibroblasts
Xu, X., Luo, S., Li, B., Dai, H., & Zhang, J. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219843827 · Cited by 45 · cited 1×
“IL-17F is able to trigger the release of IL-6 and CXC chemokines from tracheal epithelial cells, inflammatory cells, endothelial cells, and fibroblasts, supporting the hypothesis that IL-17F could modulate autoimmune and inflammatory diseases [79,80].”
Bie, Q., Song, H., Chen, X., Yang, X., Shi, S., Zhang, L., Zhao, R., Wei, L., Zhang, B., Xiong, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01699-4 · Cited by 42 · cited 1×
“Interestingly, enhanced IL-17B levels are linked with poor prognosis in patients with various types of cancer, like breast, lung, and pancreatic, reinforcing the clinical relevance of this finding [38].”
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)
Zhang, B., & Dömling, A. S. S. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2143264 · Cited by 38
Jiang, G., Liu, C., & Zhang, W. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6145 · Cited by 37 · cited 1×
“Therefore, IL-17 is markedly expressed in the bronchial mucosa of patients affected by severe asthma and drives the epithelial-to-mesenchymal transition (EMT) process when used to induce human small airway epithelial cells in in vitro cultures [52].”
Function of Act1 in IL-17 Family Signaling and Autoimmunity
Wu, L., Zepp, J. A., & Li, X. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0106-3_13 · Cited by 36 · cited 1×
“IL-17B promotes the recruitment of cells that express the chemokine receptors CXCR4 or CXCR5, and the experimental intraperitoneal administration of recombinant human IL-17B determines the chemoattraction of neutrophils, which release chemoattractants for other cells [65].”
Human Fibrosis: Is There Evidence for a Genetic Predisposition in Musculoskeletal Tissues?
Dagneaux, L., Owen, A. R., Bettencourt, J. W., Barlow, J. D., Amadio, P. C., Kocher, J. P. A., Morrey, M. E., Sánchez‐Sotelo, J., Berry, D. J., van Wijnen, A. J., et al. (2020) · The Journal of Arthroplasty · doi:10.1016/j.arth.2020.05.070 · Cited by 32 · cited 1×
“The bromodomain and extraterminal domain (BET) family proteins, consisting of BRD2, BRD3, BRD4, and BRDT, are characterized by two bromodomains that recognize and bind to lysine-acetylated histones and other acetylated proteins with different degrees of affinity.”
Interleukin-17 receptor D (Sef) is a multi-functional regulator of cell signaling
Pande, S., Yang, X., & Friesel, R. E. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00695-7 · Cited by 31 · cited 1×
“Moreover, a conserved intracellular subdomain homologous to Toll-IL-1R (TIR) domains was revealed which could be essential for signaling downstream of the IL-1 receptor and Toll-like receptors (TLRs) [24,29].”
Huang, Q., Chu, S., Yin, X., Yu, X., Kang, C., Li, X., & Qiu, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.240.269 · Cited by 29 · cited 1×
“In liver fibrosis, IL-17, operating in synergy with IL-1 β , IL-6, and IL-23, continues the inflammatory process by promoting transforming growth factor-β (TGF β ) expression in hepatic stellate cells [48,49].”
Wu, W.-P., Tsai, Y., Lin, T., Wu, M., & Lin, C. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0630-6 · Cited by 29 · cited 1×
“When created, one or both strands of the miRNA duplex can be assimilated into the RNA-induced silencing complex regulating gene transcription [107].”
Base Composition Characteristics of Mammalian miRNAs
Wang, B. (2013) · Journal of Nucleic Acids · doi:10.1155/2013/951570 · Cited by 28 · cited 2×
“Several epigenetic modifications are involved in this process, such as histone modifications, DNA demethylation, or miRNAs and lncRNAs.”
Chen, K., Campfield, B. T., Wenzel, S. E., McAleer, J. P., Kreindler, J. L., Kurland, G., Gopal, R., Wang, T., Chen, W., Eddens, T. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87168 · Cited by 25 · cited 1×
“Actually, numerous clinical trials of anti-IL-17A and IL-17RA antibodies are currently in progress [130,131].”
Role of noncoding RNAs in liver fibrosis
Li, Q., Gong, T., Huang, Y., Kang, L., Warner, C. A., Xie, H., Chen, L., & Duan, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1446 · Cited by 22 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance
Seelige, R., Washington, A., & Bui, J. D. (2017) · Cytokine · doi:10.1016/j.cyto.2016.11.017 · Cited by 21 · cited 1×
“Therefore, it is well documented that IL-17D provokes exacerbated viral infections [43,44].”
Chen, S., Zhang, X., Yang, C., Wang, S., & Shen, H. (2022) · Theranostics · doi:10.7150/thno.74809 · Cited by 21 · cited 1×
“However, knowledge of the role of IL-17Ds in the exacerbation of pulmonary fibrosis remains poorly investigated and needs clarifying studies.”
Lee, Y. K., Landuyt, A. E., Lobionda, S., Sittipo, P., Zhao, Q. S., & Maynard, C. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186351 · Cited by 20 · cited 1×
“IL-17B was demonstrated to be highly expressed during the intestinal inflammatory state and is able to induce neutrophil migration upon intraperitoneal administration, suggesting a pro-inflammatory key role [18,36,37].”
Vella, G., Ritzmann, F., Wolf, L., Kamyschnikow, A., Stodden, H., Herr, C., Slevogt, H., Bals, R., & Beißwenger, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0243484 · Cited by 18 · cited 1×
“However, knowledge of the role of IL-17Ds in the exacerbation of pulmonary fibrosis remains poorly investigated and needs clarifying studies.”
Hu, X., Zou, Y., Copland, D. A., Schewitz‐Bowers, L. P., Li, Y., Lait, P. J. P., Stimpson, M. L., Zhang, Z., Guo, S., Liang, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104333 · Cited by 17 · cited 1×
“Actually, numerous clinical trials of anti-IL-17A and IL-17RA antibodies are currently in progress [130,131].”
DGCR14 Induces Il17a Gene Expression through the RORγ/BAZ1B/RSKS2 Complex
Takada, I. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00926-14 · Cited by 16 · cited 1×
“More recently, the Food and Drug Administration has approved a novel drug, Ixekizumab, for the treatment of moderate-to-severe plaque psoriasis as well as active psoriatic arthritis.”
Zhang, Y., Chen, X., & Deng, Y. (2019) · PubMed · Cited by 16
Regulation of Experimental Autoimmune Uveoretinitis by Anti-Delta-Like Ligand 4 Monoclonal Antibody
Ishida, W., Fukuda, K., Sakamoto, S., Koyama, N., Koyanagi, A., Yagita∥, H., & Fukushima, A. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7756 · Cited by 12 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Interleukin 17 B regulates colonic myeloid cell infiltration in a mouse model of DSS-induced colitis
Zhang, X., Zhang, X., Song, X., Xiang, C., He, C., Xie, Y., Zhou, Y. Y., Wang, N., Guo, G., Zhang, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055256 · Cited by 11 · cited 1×
“IL-17B was demonstrated to be highly expressed during the intestinal inflammatory state and is able to induce neutrophil migration upon intraperitoneal administration, suggesting a pro-inflammatory key role [18,36,37].”
Yao, S.-X., Zhang, G.-S., Cao, H., Song, G., Li, Z.-T., & Zhang, W. (2015) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2015.07.021 · Cited by 10 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Towards a Unified Approach in Autoimmune Fibrotic Signalling Pathways
Sisto, M., & Lisi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109060 · Cited by 9 · cited 2×
“In recent years, growing evidence has highlighted that aberrant fibrosis is also a major pathological feature of many chronic autoimmune diseases, including scleroderma, rheumatoid arthritis (RA), Crohn’s disease, systemic lupus erythematosus (SLE), and Sjögren’s syndrome (SS) [6,7].”
Self-citationWhy do IL-17-targeted therapies have limited efficacy?
Flemming, A. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00930-5 · Cited by 3
Cited by
Smith, J. A., & Rai, V. (2024) · Biomedicines · doi:10.3390/biomedicines12091939 · Cited by 109
“…in the proliferation and migration of epidermal keratinocytes [103], fibroblast proliferation, activation, function (ECM production), senescence, and differentiation [104], and stimulates smooth muscle cell migration involving MMP-9, p38 MAPK and ERK1/2-dependent NF-κ B, and AP-1 activation [105].”
BackgroundDonniacuo, A., Mauro, A., Cardamone, C., Basile, A., Manzo, P., Dimitrov, J., Cammarota, A. L., Marzullo, L., Triggiani, M., Turco, M. C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188921 · Cited by 44
“One of the mechanisms through which IL-17 contributes to the progression of SS is the induction of epithelial– mesenchymal transition (EMT) in glandular epithelial cells, which leads to fibrosis and functional tissue loss [121].”
Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
Rolski, F., & Ma̧czewski, M. (2025) · Pharmaceuticals · doi:10.3390/ph18030313 · Cited by 34
(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
IL-17 is Associated with Disease Severity and Targetable Inflammatory Processes in Heart Failure
Baumhove, L., van Essen, B. J., Dokter, M. M., Zijlstra, S. N., Deiman, F. E., Laman, J. D., Lang, C. C., Verstappen, G. M. P. J., van Veldhuisen, D. J., van der Meer, P., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14968 · Cited by 21
Metadata
- Authors
- Sisto, M., & Lisi, S.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Sisto, Margherita
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-12-27
- Volume
- 13
- Issue
- 1
- Pages
- 164
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10780256
- OpenAlex
- W4390265558
- Cited by
- 22
- References
- 136
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 3 · 2023: 1
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- IL-17, fibrotic diseases, fibrosis, antifibrotic therapy, chronic inflammation, epigenetic regulation, IL-17 signaling, organ failure, autoimmune disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.